Tumor development was monitored every three days while anti- PD1/PD-L1 therapies were given every three days and HMOX1/MMP9/TNFRSF11B antibody treatments were given every day until tumor capture on the ninth day. The gene discussed is MMP9; the disease is neoplasm.